Parkinson DiseaseFOGNCT02387281
Freezing of Gait: Clinical, Cognitive, and Imaging Features
An observational study of Parkinson Disease, run by Emory University at 2 sites in United States.
Trial summary
Freezing of gait (FOG) is among the most disabling motor features of Parkinson disease (PD) and is present in other forms of parkinsonism as well. FOG is a brief (usually lasting <30 seconds) episode of absence or a greatly reduced forward movement of the feet despite intention to walk. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Parkinson Disease
- How many people
- 60 participants
- Where
- 2 sitesUnited States
- Study dates
- Mar 2015to 13 Nov 2017
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Freezing of gait (FOG) patients with Parkinson disease (PD) will be selected from the Emory Movement Disorders Center.
Inclusion Criteria for Parkinson disease (PD) subjects with freezing of gait (FOG):
- Diagnosis of PD by United Kingdom Brain bank criteria
- Hoehn \& Yahr stage I-IV
- Levodopa treated and responsive
- Able to manage 12 hours off dopaminergic medication
- Age 18-85 years
- Presence of FOG by history and seen by examiner at their clinical office visit or in a video taken at home
- Able sign a consent document and willing to participate in all aspects of the study
- Able to have an MRI scan (no pacemakers or history of claustrophobia)
Exclusion Criteria for Parkinson disease (PD) subjects with freezing of gait (FOG):
- Dementia that precludes completing study protocol
- Stage V PD - unable to walk independently when "off"
- History of FOG without ever being seen to have it
- Atypical parkinsonism: Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), Corticobasal Degeneration (CBD), Vascular Parkinsonism
- Treatment with medications that cause parkinsonism: drug-induced parkinsonism
- Any neurological or orthopedic disorders that interfere with gait
- Treatment with medications that will interfere with NET-PET (norepinephrine transporter-positron emission tomography) ligand binding
- Noradrenergic drugs: methylphenidate, atomoxetine, serotonin-norepinephrine reuptake inhibitors (e.g., venlafaxine)
- Absence or loss of levodopa response
- Any contraindications for MRI scan including pacemaker, deep brain stimulator, bladder stimulator, etc.
Inclusion Criteria for Parkinson disease (PD) subjects but no freezing of gait (FOG):
- Diagnosis of PD by United Kingdom Brain bank criteria
- Hoehn \& Yahr stage I-IV
- Levodopa treated and responsive
- Able to manage 12 hours off dopaminergic medication
- Age 18-85 years, age, gender and duration matched to the PD with FOG recruits
- Absence of FOG by history and by exam, confirmed by caregiver and FOG-Q item 3 score of 0.
- Able sign a consent document and willing to participate in all aspects of the study
- Able to have an MRI scan (no pacemakers or history of claustrophobia)
Exclusion Criteria for Parkinson disease (PD) subjects but no freezing of gait (FOG):
- Dementia that precludes completing study protocol
- Stage V PD - unable to walk independently when off.
- History of FOG at any time
- Atypical parkinsonism: Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), Corticobasal Degeneration (CBD), Vascular Parkinsonism
- Treatment with medications that cause parkinsonism: drug-induced parkinsonism
- Any neurological or orthopedic disorders that interfere with gait
- Treatment with medications that will interfere with NET-PET ligand binding
- Absence or loss of levodopa response
- Any contraindications for MRI scan including pacemaker, deep brain stimulator, bladder stimulator, etc.
Inclusion Criteria for subjects with freezing of gait (FOG) but not Parkinson disease (PD):
- Diagnosis of Primary Progressive Freezing gait by accepted Criteria 71
- Diagnosis of atypical parkinsonism; Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA) with predominant and early onset FOG.
- Hoehn \& Yahr Stage I-IV parkinsonism
- Limited response to Levodopa but FOG unresponsive, but may be on levodopa or other dopaminergic medications
- Age 18-85 years
- Presence of FOG by history and seen by examiner at their clinical office visit or in a video taken at home
- MRI scan demonstrating no structural lesions: stroke, tumor or hydrocephalous
- Able sign a consent document and willing to participate in all aspects of the study
- Able to have an MRI scan (no pacemakers or history of claustrophobia).
Exclusion Criteria for subjects with freezing of gait (FOG) but not Parkinson disease (PD):
- Dementia that precludes completing study protocol
- Stage V Parkinsonism - unable to walk independently.
- Treatment with medications that cause parkinsonism: drug-induced parkinsonism
- MRI scan demonstrating structural lesions or hydrocephalous
- Notable levodopa response suggesting a diagnosis of PD including motor fluctuations or dyskinesia.
- Any neurological or orthopedic disorders that interfere with gait.
- Treatment with medications that will interfere with NET-PET ligand binding.
- Any contraindications for MRI scan including pacemaker, deep brain stimulator, bladder stimulator, etc.
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Emory Movement Disorders Center
Atlanta, Georgia, 30329
Wesley Woods Center
Atlanta, Georgia, 30329
About this study
Freezing of gait (FOG) is among the most disabling motor features of Parkinson disease (PD) and is present in other forms of parkinsonism as well. FOG is a brief (usually lasting <30 seconds) episode of absence or a greatly reduced forward movement of the feet despite intention to walk. It typically occurs when patients initiate gait (so-called "start hesitation") and when attempting to turn. It is a leading cause of falls and often results in a wheelchair-dependent state. FOG greatly interferes with activities of daily living, causes social isolation and poor quality of life.
FOG is one of the least understood features of PD. It possibly may develop independent of the other motor features of the disease, and be caused by specific pathological changes in the brain. Previous studies on FOG have shown conflicting information and have not lead to clear understanding of the pathophysiology. One key reason for this is that there appears to be multiple subtypes which have rarely been taken into account.
The purpose of this study is to show that different types of FOG exist and to see if there is a connection to cognitive differences or gait patterns.
Read the detailed description
This study is an observational study to assess FOG via using multiple methods such as: clinical features, imaging, cognition and dopamine blood levels. The study consists of four parts (plus an optional fifth part) that will be completed over two-three separate days within a 30 day span. The four parts will not necessarily be performed in this order. Part one will be clinical and written questionnaire assessments of PD and FOG followed by 3D motion capture evaluations. Part two are cognitive or neuropsychiatric assessments. Part three is a magnetic resonance image (MRI) to examine the brain structure. Part four is Positron Emission Tomography (PET) imaging scan that measures norepinephrine transporter levels. The optional part 5 is a lumbar puncture that will measure cerebrospinal fluid catecholamines and proteomics.
- Conditions
- Parkinson Disease
- Keywords
- Freezing of gait
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| PD with FOG "on" | Subjects diagnosed with Parkinson disease (PD) and sub-categorized as "on" freezing of gait (FOG) based on evaluation using motion capture | |
| PD with FOG "off" | Subjects diagnosed with Parkinson disease (PD) and sub-categorized as "off" freezing of gait (FOG) based on evaluation using motion capture | |
| PD without FOG | Subjects with Parkinson disease (PD) and an absence of freezing of gait (FOG) | |
| Non-PD with FOG | Subjects with freezing of gait (FOG) and an absence of Parkinson disease (PD) (exception granted for those with FOG and atypical parkinsonism: PSP or MSA) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III
MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The Part III motor examination has 18 items, which are rated from 0-4, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe.
Measured: Baseline
Response to levodopa
Subjects will be assessed in the "on" and "off" states to classify them properly according to pharmacological response to levodopa
Measured: Baseline
Classification of FOG using motion capture
Classifying of FOG ("on" and "off") will be done measuring gait physiology though 3-dimensional motion capture between and during FOG episodes.
Measured: Baseline
Plasma concentrations of levodopa
Levodopa plasma concentrations measured by modified high-performance liquid chromatography with electrochemical detection method during "on" and "off" episodes.
Measured: Baseline
Secondary outcomes (25)
Dot Counting task score
Dot counting is a verbal working memory task where the examinee looks at a computer screen with a mixed array of green circles, blue circles and blue squares, and instructed to count all of the blue circles on the screen one at a time and remember the final total. Once the examinee finishes counting the blue circles on one screen, the examiner switches the display to a different mixed array of green circles, blue circles and blue squares. The examinee is instructed to count the blue circles in the new display. The number of different displays presented to the examinee in each trial increases from two to seven over six trials. After counting the blue circles on all of the displays presented within a trial, the examinee recalls the total number of blue circles in each of the different displays in the order in which they were presented. The task includes six trials with possible scores ranging from 0 to 27.
Measured: Baseline
N-back task score
The n-back paradigm is a widely used measure to assess spatial working memory. The 1-back requires maintaining and updating 1 location at a time. The examinee is shown a series of 2.4 cm white squares that appear in 15 different locations on a black computer screen. Each square is presented for 1000 ms. All of the locations are equidistant from the center of the screen. The 1-back consists of one block of 30 trials, ten of which match the location of the previous square, and 20 that are in a different location. Scoring is based on the number of accurate responses out of 30 trials.
Measured: Baseline
Flanker task score
The Flanker task assesses an individual's ability to inhibit a prepotent response. A row of five arrows is presented in the center of the screen. The examinee is required to indicate whether the centrally presented arrow is pointing either to the left or right by pressing the left or right arrow key. The examinee is presented with two different conditions during the task, incongruent and congruent. In the congruent trials, the non-target arrows point in the same direction as the target arrow and in the incongruent trials they point in the opposite direction.The stimuli are presented in a random order with each condition being presented 24 times resulting in 48 total trials. Scoring is based on the number of accurate responses out of 48 trials.
Measured: Baseline
Dimensional Set Shifting task score
The Dimensional Set Shifting task requires the individual to alternate between responding to shape vs. color of stimuli. Examinees are required to match a stimulus on the top of the screen to one of two stimuli in the lower corners of the screen. In task-homogeneous blocks, participants perform either Task A (e.g., classifying shapes) or Task B (e.g., classifying colors). In task-heterogeneous blocks, participants alternate between the two tasks pseudo-randomly. The combination of task-homogeneous and task-heterogeneous blocks allows measurement of general switch costs (latency differences between heterogeneous and homogeneous blocks) and specific switch costs (differences between switch and non-switch trials within the heterogeneous block). Scoring is based on the number of accurate responses out of 104 trials.
Measured: Baseline
Digit Span Test score
The digit span test forward assesses attention and short-term memory. The digit span test backward assesses measures working memory. For the forward test, the examinee is told to listen carefully because the examiner will say a series of numbers and ask him/her to repeat them back to in the same order. For the backward test, the examiner will ask the examinee to repeat the numbers backwards, that is, by starting with the last number said and going backwards to the first number said. This process continues until the examinee can no longer remember either the full sequence of numbers or the correct order. Both forward and reverse trials are given twice. The Digit Span test is scored by the amount of numbers the examinee was able to remember in each test. The examiner must add the total number of correct sequences, backwards and forwards.
Measured: Baseline
Number of seconds required to complete Trail Making Test (TMT): Trails A and Trails B
Trail A assesses scanning ability and psychomotor speed. Trail B assesses executive function. In Part A, the circles are numbered 1 - 25, and the participant should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1 - 13) and letters (A - L); as in Part A, the participant draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.). The participant should be instructed to connect the circles as quickly as possible. The participant is timed as he or she connects the "trail." If the participant makes an error, point it out and allow the participant to correct it. Errors affect the participant's score only in that the correction of errors is included in the completion time for the task. Participants are scored by the number of seconds taken to complete the task, with high scores revealing greater impairment.
Measured: Baseline
Wisconsin Card Sorting Test (WCST) score
The WCST measures cognitive flexibility and problem solving skills. The WCST consists of a pack of 4 stimulus cards and 48 response cards which are devised so that each card contains from 1 to 4 identical figures of a single color. Individually administered, it requires the participant to sort the cards according to different principles (ie, by color, form, or number). As the test progresses, there are unannounced shifts in the sorting principle which require the participant to alter his or her approach.The 'number of categories' measures the number of correct responses. The percentage of perseverative errors provides the concentration of perseverative errors in relation to the overall test performance.
Measured: Baseline
Brief Visuospatial Memory Test score
Brief Visuospatial Memory Test (BVMT) is a measure of visuospatial memory. This task includes three trials of six geometric figures printed on separate pages. The participant views the stimulus page for 10 seconds and is asked to draw as many of the figures as possible in their correct location on a paget. A Delayed Recall Trial is administered after a 30-minute delay. Scoring is based on accuracy of the figure as well as its location on the page. A range of 0-12 per trial is possible (0-36 total). Higher scores are better.
Measured: Baseline
Hopkins Verbal Memory Test Total Recall score
Hopkins Verbal Learning Test (HVLT) provides a brief assessment of immediate recall. It is administered by reading the words aloud, then asking the participant to verbally repeat the list of words (immediately), and identify the words from a word list that is presented verbally. The participant is read a list of 12 words and is then asked to recall as many of the words as possible. Tasks include three learning trials, which, when combined produce a total recall score.The HVLT total recall score ranges from 0 to 36 with 36 being the highest and best possible score.
Measured: Baseline
Hopkins Verbal Memory Test Delayed Recall score
Hopkins Verbal Learning Test (HVLT) provides a brief assessment of delay recall. It is administered by reading the words aloud, then asking the participant to verbally repeat the list of words (after a 20-25 minute delay), and identify the words from a word list that is presented verbally. The participant is read a list of 12 words and is then asked to recall as many of the words as possible. The HVLT delayed recall score ranges from 0 to 12 with 12 being the highest and best possible score.
Measured: Baseline
Number of correct trials in Morris Water Maze Paradigm
Morris Water Maze (MWM) Paradigm is used to study spatial memory and learning. The MWM is a virtual water maze paradigm in which the hidden platform is continually re-located. The participant has to locate a hidden platform to escape the water. The number of correct trials will be the score.
Measured: Baseline
Number of correct trials in Recognition of Scenes
Recognition of Scenes is used to assess emotional memory. The Recognition of Scenes task requires the participant to recall various scenes that have different emotional valences. The number of correct trials will be the score.
Measured: Baseline
Number of correct responses for Confrontation Naming task
Confrontation naming tasks are used to assess impairments of word-finding abilities in individuals with various types of neurologic impairments. Confrontation naming involves the selection of a specific label corresponding to a viewed stimulus, usually a picture, of a viewed object or action. The number of correct responses will be the score.
Measured: Baseline
Verbal Fluency in Naming Categories
Fluency is measured by timed word retrieval. Participants are given 60 seconds to name as many words as possible within a given category. The more words named, the better cognition
Measured: Baseline
Benton Judgment of Line Orientation Test
Line orientation assesses spatial perception and orientation without requiring a motor output. The Benton Judgment of Line Orientation Test measures a person's ability to match the angle and orientation of lines in space. Participants are asked to match two angled lines to a set of 11 lines that are arranged in a semicircle and separated 18 degrees from each other.The test is a standardized test with 30 items with the minimum score being 0, indicating low visual spatial cognition and the maximum score being 30, indicating high visual spatial cognition.
Measured: Baseline
Number of correct responses for Mental Rotation Task
Mental rotation is the ability to rotate mental representations of two-dimensional and three-dimensional objects as it is related to the visual representation of such rotation within the human mind.In a mental rotation test, the participant is asked to compare two 3D objects (or letters), often rotated in some axis, and state if they are the same image or if they are mirror images (enantiomorphs). Commonly, the test will have pairs of images each rotated a specific amount of degrees (e.g. 0°, 60°, 120° or 180°). Some pairs will be the same image rotated, and others will be mirrored. The participant will be shown a set number of the pairs. The participant will be scored on how accurately they can distinguish between the mirrored and non-mirrored pairs. The number of correct responses will be the score.
Measured: Baseline
Scale for the Assessment of Positive Symptoms (SAPS) score
Scale for the Assessment of Positive Symptoms (SAPS) assesses the presence of psychotic symptoms. There are 34 items rated on a scale of 0-5 with 0=none and 5=severe for a minimum score of 0 and a maximum score of 170. There are 4 subscales: Hallucinations (minimum score 0; maximum score 35); Delusions (minimum score 0; maximum score 65); Bizarre Behavior (minimum score 0; maximum score 25); Positive Formal Thought Disorder (minimum score 0; maximum score 45). Each subscale contains one additional question as a Global Rating - or overall measure for that particular subscale. The sum of these questions constitutes the Total Global Score (minimum 0, maximum 20). The values for the Global items are included in the Total Composite score. In each case, the higher the score, the greater the severity of symptoms.
Measured: Baseline
Beck Depression Inventory (BDI) score
Beck Depression Inventory (BDI) is a self-report rating inventory measuring characteristic attitudes and symptoms of depression consisting of 21 items with each item rated on a four point scale (0=not present to 3=severe). The accepted ranges are as follows: 0 to 9 indicates no depression, 10 to 18 indicates mild to moderate depression, 19 to 29 indicates moderate to severe depression and 30 to 63 indicates severe depression.
Measured: Baseline
Beck Anxiety Inventory (BAI) score
Beck Anxiety Inventory (BAI) is a self-report rating inventory measuring general anxiety consisting of 21 items with each item rated on a four point scale (0=not present to 3=severe). Scores range from 0-63, with higher scores indicating greater anxiety.
Measured: Baseline
Questionnaire for Impulsive-Compulsive disorders in Parkinson's disease (QUIP)
Questionnaire for Impulsive-Compulsive disorders in Parkinson's disease (QUIP) is a rating scale designed to measure severity of symptoms and support a diagnosis of impulse control disorders and related disorders in Parkinson's disease. QUIP has four primary questions (pertaining to commonly reported thoughts, urges/desires, and behaviors associated with Impulse control disorders (ICDs)), each applied to the 4 ICDs (compulsive gambling, buying, eating, and sexual behavior) and 3 related disorders (medication use, punding, and hobbyism). It uses a 5-point Likert scale (score 0-4 for each question) to gauge the frequency of behaviors. Scores for each ICD and related disorder range from 0 to 16, with a higher score indicating greater severity (ie, frequency) of symptoms. The total QUIP score for all ICDs and related disorders combined ranges from 0 to 112.
Measured: Baseline
New Freezing of Gait Questionnaire (NFOG-Q) score
The NFOG-Q is used to quantify FOG severity and frequency in the daily living. It is a self-report measure that begins with the presentation of a short video to illustrate FOG during walking, turning and starting gait and then follows with questions related to frequency and duration of each type of FOG episode. Part I detects the presence of FOG using a dichotomous item in which individuals are classified as a freezer (FR) or a non-freezer (NFR). Parts II and III are designed for FRs only, providing a total summed score between 0 and 28. Part II (items 2-6, scoring range 0-19) rated the severity of FOG based on its duration and frequency. Part III rates the impact of FOG on daily life (items 7-9, scoring range 0-9).
Measured: Baseline
Measurement of neuromelanin-containing neurons in the locus ceruleus and substantia nigra
The high-resolution neuromelanin images using a magnetic resonance imaging (MRI) technique will examine noradrenergic neurons in the brain.
Measured: Baseline
Measurement of norepinephrine transporter levels
Positron emission tomography (PET) is a technique for measuring the 3-dimensional distribution of radioactive tracers in the living human. The norepinephrine transporter (NET) ligand, [11C]MeNER, with PET imaging will measure changes in norepinephrine terminals in key brain regions and compare FOG subtypes and non-FOG PD.
Measured: Baseline
Cerebrospinal fluid (CSF) biomarkers
Cerebrospinal fluid (CSF) collected via lumbar puncture to measure catecholamines and proteomics.
Measured: Baseline
Montreal Cognitive Assessment (MoCA) score
The Montreal Cognitive Assessment (MoCA) is a brief 30-point screening instrument that identifies subjects with mild cognitive impairment. Total MoCA score represents the sum of these 30-points, with a lower score indicating greater cognitive impairment. 30 is the maximum score, with a score of 26 or higher considered normal and below 26 indicative of Mild Cognitive Impairment.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2015 (estimated)
- Study startMar 2015
- Primary completion13 Nov 2017
- Study completion13 Nov 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- More trials run by Emory UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Emory University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Stewart Factor, Emory University
- Investigators
- Stewart Factor, DO, Principal investigator, Emory University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02387281
- Sponsor's protocol ID
- IRB00073518
- Acronym
- FOG
- Status last verified
- Apr 2018
- First submitted
- 6 Mar 2015
- Last updated
- 6 Apr 2018
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 6 Apr 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Freezing of Gait: Clinical, Cognitive, and Imaging Features
- ClinicalTrials.gov ID
- NCT02387281
- Acronym / sponsor ID
- FOG / IRB00073518
- Conditions
- Parkinson Disease
- Keywords
- Freezing of gait
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Emory UniversityUniversity, hospital or other
- Study start
- Mar 2015
- Primary completion
- 13 Nov 2017 (actual)
- Study completion
- 13 Nov 2017 (actual)
- First posted
- 12 Mar 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Freezing of gait (FOG) is among the most disabling motor features of Parkinson disease (PD) and is present in other forms of parkinsonism as well. FOG is a brief (usually lasting <30 seconds) episode of absence or a greatly reduced forward movement of the feet despite intention to walk. It typically occurs when patients initiate gait (so-called "start hesitation") and when attempting to turn. It is a leading cause of falls and often results in a wheelchair-dependent state. FOG greatly interferes with activities of daily living, causes social isolation and poor quality of life.
FOG is one of the least understood features of PD. It possibly may develop independent of the other motor features of the disease, and be caused by specific pathological changes in the brain. Previous studies on FOG have shown conflicting information and have not lead to clear understanding of the pathophysiology. One key reason for this is that there appears to be multiple subtypes which have rarely been taken into account.
The purpose of this study is to show that different types of FOG exist and to see if there is a connection to cognitive differences or gait patterns.
Detailed description
This study is an observational study to assess FOG via using multiple methods such as: clinical features, imaging, cognition and dopamine blood levels. The study consists of four parts (plus an optional fifth part) that will be completed over two-three separate days within a 30 day span. The four parts will not necessarily be performed in this order. Part one will be clinical and written questionnaire assessments of PD and FOG followed by 3D motion capture evaluations. Part two are cognitive or neuropsychiatric assessments. Part three is a magnetic resonance image (MRI) to examine the brain structure. Part four is Positron Emission Tomography (PET) imaging scan that measures norepinephrine transporter levels. The optional part 5 is a lumbar puncture that will measure cerebrospinal fluid catecholamines and proteomics.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| PD with FOG "on" | – | –Subjects diagnosed with Parkinson disease (PD) and sub-categorized as "on" freezing of gait (FOG) based on evaluation using motion capture |
| PD with FOG "off" | – | –Subjects diagnosed with Parkinson disease (PD) and sub-categorized as "off" freezing of gait (FOG) based on evaluation using motion capture |
| PD without FOG | – | –Subjects with Parkinson disease (PD) and an absence of freezing of gait (FOG) |
| Non-PD with FOG | – | –Subjects with freezing of gait (FOG) and an absence of Parkinson disease (PD) (exception granted for those with FOG and atypical parkinsonism: PSP or MSA) |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Freezing of gait (FOG) patients with Parkinson disease (PD) will be selected from the Emory Movement Disorders Center.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III
Time frame: Baseline
MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The Part III motor examination has 18 items, which are rated from 0-4, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe.
Response to levodopa
Time frame: Baseline
Subjects will be assessed in the "on" and "off" states to classify them properly according to pharmacological response to levodopa
Classification of FOG using motion capture
Time frame: Baseline
Classifying of FOG ("on" and "off") will be done measuring gait physiology though 3-dimensional motion capture between and during FOG episodes.
Plasma concentrations of levodopa
Time frame: Baseline
Levodopa plasma concentrations measured by modified high-performance liquid chromatography with electrochemical detection method during "on" and "off" episodes.
25 secondary outcomes
Dot Counting task score
Time frame: Baseline
N-back task score
Time frame: Baseline
Flanker task score
Time frame: Baseline
Dimensional Set Shifting task score
Time frame: Baseline
Digit Span Test score
Time frame: Baseline
Number of seconds required to complete Trail Making Test (TMT): Trails A and Trails B
Time frame: Baseline
Wisconsin Card Sorting Test (WCST) score
Time frame: Baseline
Brief Visuospatial Memory Test score
Time frame: Baseline
Hopkins Verbal Memory Test Total Recall score
Time frame: Baseline
Hopkins Verbal Memory Test Delayed Recall score
Time frame: Baseline
Number of correct trials in Morris Water Maze Paradigm
Time frame: Baseline
Number of correct trials in Recognition of Scenes
Time frame: Baseline
Number of correct responses for Confrontation Naming task
Time frame: Baseline
Verbal Fluency in Naming Categories
Time frame: Baseline
Benton Judgment of Line Orientation Test
Time frame: Baseline
Number of correct responses for Mental Rotation Task
Time frame: Baseline
Scale for the Assessment of Positive Symptoms (SAPS) score
Time frame: Baseline
Beck Depression Inventory (BDI) score
Time frame: Baseline
Beck Anxiety Inventory (BAI) score
Time frame: Baseline
Questionnaire for Impulsive-Compulsive disorders in Parkinson's disease (QUIP)
Time frame: Baseline
New Freezing of Gait Questionnaire (NFOG-Q) score
Time frame: Baseline
Measurement of neuromelanin-containing neurons in the locus ceruleus and substantia nigra
Time frame: Baseline
Measurement of norepinephrine transporter levels
Time frame: Baseline
Cerebrospinal fluid (CSF) biomarkers
Time frame: Baseline
Montreal Cognitive Assessment (MoCA) score
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Apr 2018.
Related trials for Parkinson Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stewart Factor, DO principal investigator
Emory University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Parkinson Disease, run by Emory University at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Apr 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (time frame: Baseline). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2018.